

RESEARCH ARTICLE

Open Access

Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study

Adriana C Vidal¹, Cocoa Tucker², Joellen M Schildkraut³, Ricardo M Richardson², Megan McPhail^{4,5}, Stephen J Freedland^{4,5,6,7}, Cathrine Hoyo¹ and Delores J Grant^{2*}

Abstract

Background: We have previously shown that a functional polymorphism of the *UGT2B15* gene (rs1902023) was associated with increased risk of prostate cancer (PC). Novel functional polymorphisms of the *UGT2B17* and *UGT2B15* genes have been recently characterized by *in vitro* assays but have not been evaluated in epidemiologic studies.

Methods: Fifteen functional SNPs of the *UGT2B17* and *UGT2B15* genes, including *cis*-acting *UGT2B* gene SNPs, were genotyped in African American and Caucasian men (233 PC cases and 342 controls). Regression models were used to analyze the association between SNPs and PC risk.

Results: After adjusting for race, age and BMI, we found that six *UGT2B15* SNPs (rs4148269, rs3100, rs9994887, rs13112099, rs7686914 and rs7696472) were associated with an increased risk of PC in log-additive models ($p < 0.05$). A SNP *cis*-acting on *UGT2B17* and *UGT2B15* expression (rs17147338) was also associated with increased risk of prostate cancer (OR = 1.65, 95% CI = 1.00-2.70); while a stronger association among men with high Gleason sum was observed for SNPs rs4148269 and rs3100.

Conclusions: Although small sample size limits inference, we report novel associations between *UGT2B15* and *UGT2B17* variants and PC risk. These associations with PC risk in men with high Gleason sum, more frequently found in African American men, support the relevance of genetic differences in the androgen metabolism pathway, which could explain, in part, the high incidence of PC among African American men. Larger studies are required.

Background

Prostate cancer is the second leading cause of cancer-related deaths in men, after lung cancer [1]. The incidence of prostate cancer has increased over the past twenty years and African American men have been disproportionately affected compared to other racial/ethnic groups [2-7]. In the U.S., the incidence of prostate cancer among African Americans is more than 60% higher than in Caucasians, and the mortality rate in African Americans is twice that of Caucasian men [8,9]. Although differences in incidence and mortality rates may be due, in part, to race/ethnicity, socioeconomic conditions and availability of health care

[10], familial aggregation studies suggest that genetic factors may also be contributing to prostate cancer demographic disparity. Candidate gene approaches involving hormone metabolic pathways have been examined in prostate cancer association studies, however results from these studies have not been replicated [11,12]. Nonetheless, current therapies are primarily targeted at specific androgen biosynthetic pathways [13], thus, improved knowledge on genetic variants associated with both androgen metabolism and prostate cancer risk is important.

The *UDP-glucuronosyltransferase (UGT)* genes code for enzymes that convert a diverse group of xenobiotic and endobiotic substances into lipophilic compounds, facilitating clearance from the body as part of the phase

* Correspondence: dgrant@ncsu.edu

²Department of Biology and Cancer Research Program, JLC-Biomedical/ Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA

Full list of author information is available at the end of the article

II liver detoxification system [14]. These enzymes are subdivided into families according to similarities in amino acid sequence and target substrates dictated by the specificity of their amino-terminal ends [15]. A specific subfamily, UGT2B, includes two enzymes, UGT2B17 and UGT2B15, which are also expressed extrahepatically in the basal and luminal epithelium of the prostate, respectively. These enzymes exhibit specificity for androgen metabolites such as testosterone, dihydrotestosterone (DHT), androsterone (ADT), and androstane-3 α ,17 β -diol (3 β -diol) in prostate tissue and cell lines [16,17].

Functional polymorphisms of the *UGT2B* gene family such as the copy number variant (CNV) of *UGT2B17*, and the aspartic acid (D or nucleotide G) to tyrosine substitution (Y or nucleotide T) found in codon 85 of the *UGT2B15* gene (*UGT2B15*^{D85Y}, rs1902023) have been identified [18,19]. Studies suggest that men with 0 copies of the *UGT2B17* gene are unable to break down testosterone through the UGT2B pathway and subsequently secrete negligible amounts of urinary testosterone compared to men with at least one copy of *UGT2B17* [18,20]. Experimental evidence showed that the minor allele (T) of the *UGT2B15* variant, *UGT2B15*^{D85Y}, causes the enzyme to have an increased V_{max} activity when compared to the presence of the major allele (G) [19]. Subsequently, the resulting phenotype of this *UGT2B15* polymorphism is a quicker androgen metabolite clearance which may raise the “effective” amount of steroids within the prostate and decrease risk for prostate cancer [21]. These two major *UGT2B* variants (the CNV in *UGT2B17* and the polymorphism in *UGT2B15*) have been evaluated in relation to prostate cancer risk, with inconsistent findings [22-32]. Discrepancies could have been due to the genetic heterogeneity of the populations studied, as well as variable sample sizes of these populations. We have recently shown that individuals with a major allele (G) of the *UGT2B15*^{D85Y} polymorphism (rs1902023) have higher risk of prostate cancer when compared to individuals homozygous for the “rapid clearance” minor allele (Y) [33]. In the same study, the *UGT2B17* CNV showed no association with prostate cancer risk [33]. Recently, an additional 7 novel *UGT2B15* SNPs that are in strong linkage disequilibrium (LD) with the *UGT2B15*^{D85Y} gene variant, have been identified by re-sequencing the promoter and exon one regions of the *UGT2B15* gene, using DNA samples from Yoruba (YRI), CEPH/European (CEU), and Japanese/Chinese (ASN) populations [34]. Most of these *UGT2B* variants have not been evaluated in relation to prostate cancer risk in population-based studies or in studies that included African American men. In this present work, we examined associations between functional SNPs of *UGT2B17*, *UGT2B15* and three other related *UGT2B* SNPs, and prostate cancer risk among African American and Caucasian men.

Methods

Study population

The details of participant accrual for this case control study have been previously reported [35]. In brief, male subjects from the Durham Veterans Affairs Medical Center (DVAMC) in Durham, North Carolina, who were undergoing a prostate needle biopsy between January 2007 and October 2011, were consecutively contacted in a hospital-based, case control study. Eligibility criteria for cases included age >18 years, undergoing a prostate biopsy for concerns of potential prostate cancer after presentation with elevated PSA and/or abnormal digital rectal examination, and prostate cancer positive classification by pathological review of biopsy tissue. Of the 759 men with a biopsy indication who were screened for eligibility, 539 (759/539 = 71% participation rate) provided written consent to participate. Twenty two men elected not to follow through and of the 517 men that underwent a biopsy, 233 had a biopsy with histological evidence of prostate cancer. Controls were recruited from the DVAMC Internal Medicine Clinic; eligibility criteria were age >18 and having a PSA test conducted at the DVAMC within the same time frame, but not recommended to undergo biopsy. Of the 768 men who met eligibility criteria for controls, 377 provided written consent (768/377 = 49% participation rate). Questionnaires were administered to prostate cancer cases prior to biopsy and to controls to assess risk factors including race and age. Institutional Review Board approval was obtained at North Carolina Central University, Duke University, and the DVAMC and all patients signed an informed consent prior to enrollment.

Genotyping

UGT2B variants were selected for genotyping from previous published reports as well as dbSNP and SNP Tags from the Genome Variation Server (GVS) (Table 1). Eight were from the *UGT2B15* gene, 4 were from the *UGT2B17* gene and 3 were *cis*-acting on the *UGT2B15* and/or *UGT2B17* gene expression. *UGT2B15* SNPs that were genotyped for this study include rs1580083, rs1960733 (formerly rs34050522), rs9994887 (formerly rs35513228), rs13112099, rs7866914 (formerly rs34027331), rs7696472, rs4148296, rs3100 and rs17221777. *UGT2B15* SNPs rs1580083, rs1960733 (formerly rs34050522), rs9994887 (formerly rs35513228), rs13112099, rs7686914 (formerly rs34027331) and rs7696472 were identified from the re-sequencing of the *UGT2B15* promoter and exon 1 in 56 HapMap samples from YRI, CEU, and East Asian (ASN) populations [34]. Other *UGT2B15* SNPs genotyped, rs4148296 (T523K) and rs3100 (3'UTR) were characterized by differential allelic expression assays and re-sequencing, respectively [36]. The final *UGT2B15* SNP, rs17221777, was identified in a previous study [18].

Table 1 UGT2B15 and UGT2B17 genotyped SNPs and Minor alleles

SNP	Function class	Minor allele/MAF			Reference
		All	Afr. American	Caucasian	
UGT2B15 SNPs					
rs1580083	Promoter	T/0.74	0.70	0.80	34
rs1960773	Promoter (Nrf2)	T/0.73	0.70	0.76	34
rs9994887	Promoter	A/0.73	0.67	0.78	34
rs13112099	Promoter	T/0.74	0.70	0.78	34
rs7686914	Promoter	T/0.73	0.68	0.78	34
rs7696472	Promoter	G/0.73	0.68	0.76	34
rs4148269	Nonsyn (T523K)	C/0.70	0.70	0.85	36
rs3100	3'UTR	T/0.72	0.53	0.85	36
UGT2B17 SNPs					
rs59678213	Promoter (FoxA1)	C/0.32	0.24	0.67	37
rs7435827	Intron	G/0.60	0.30	0.76	GVS
rs7686008	Intron	T/0.18	0.34	0.06	GVS
rs7671342	Intron	G/0.41	0.41	0.41	GVS
Cis acting on UGT2B expression					
rs6822259 [^]	Intergenic	C/0.32	0.30	0.30	38
rs17147338 ^{^^}	Intergenic	T/0.16	0.30	0.079	38
rs2168047 ^{^^}	Distal promoter	A/0.67	0.73	0.63	38

[^]Acis-acting on UGT2B17 expression (36).

^{^^}Acis-acting on UGT2B17 and UGT2B15 expression (36).

GVS - genome variation server.

UGT2B17 SNPs that were genotyped for this study SNPs include rs72551386, rs59678213, rs7435827, rs7686008, rs7671342, rs35994121, and rs35140421. UGT2B17 SNPs rs7435827, rs7686008, rs7671342, rs35994121, and rs35140421 were identified as UGT2B17 Tag SNPs in the GVS and dbSNP databases. UGT2B17 SNP rs59678213 was identified as a novel polymorphism in a transcriptional binding site in the promoter region of UGT2B17 [37]. Four SNPs were genotyped in this study, rs6822259, rs17147338, rs2168047 and rs4557343, that were identified in a SNP discovery study and characterized as cis-acting on UGT2B17 (rs6822259), UGT2B15 (rs4557343), and UGT2B17 and UGT2B15 (rs17147338, rs2168047) gene expression [38]. Of the twenty SNPs, five were excluded from analysis because they were either monoallelic (rs72551386, rs17221777, rs3599412, and rs3514942) in the study population or the genotyping assay failed (rs455734).

DNA was isolated from peripheral blood by standard DNA isolation (Qiagen Inc., Valencia, CA, U.S.A.) and quantified by ultraviolet spectrophotometry. Prior to genotyping, DNA concentration was determined using PicoGreen assay (Life Technologies, Gaithersburg, MD) and measured using the fluorescence intensity measurements plotted against a standard curve that was generated from the average fluorescence intensity of standards run

Table 2 Risk factor characteristics for prostate cancer participants

Risk factors	Cases n = 233 n (%)	Controls n = 342 n (%)	p-value
Age - mean (SD)	63.34 (6.37)	61.32 (7.49)	p = 0.005
Height (in.)	69.65 (2.92)	69.91 (3.03)	p = 0.31
Obesity (BMI)	29.25 (5.60)	30.77 (6.05)	p = 0.002
Race			p = <.0001
African American	146 (62.66)	140 (40.93)	
Caucasian	87 (37.34)	202 (59.06)	
Family history PC			p = 0.16
Yes	32 (13.73)	34 (9.94)	
No	201 (86.26)	308 (90.05)	
Tobacco use			p = 0.43
Yes	225 (96.56)	334 (97.66)	
No	8 (3.43)	8 (2.33)	
Gleason sum <8 (134 Black/77 White)	211 (91.34)	NA	
≥8 (10 Black/10 White)	20 (8.66)		

Table 3 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC

SNP # Allele	Cases n (%)	Controls n (%)	OR (95% CI)*
UGT2B15			
rs1580083			
TT	2 (0.86)	5 (1.47)	Reference
TA	150 (64.38)	249 (73.45)	2.32 (0.23-23.81)
AA	81 (34.76)	85 (25.07)	3.24 (0.31-33.93)
AA/TA	231 (99.14)	334 (98.52)	2.54 (0.25-26.00)
Log additive			1.43 (0.91-2.26)
rs1960773			
TT	1 (0.43)	5 (1.47)	Reference
GT	144 (62.61)	244 (71.98)	-
GG	85 (36.96)	90 (26.55)	-
TT/GT	229 (99.56)	334 (98.52)	-
Log additive			-
rs9994887			
AA	38 (16.31)	91 (26.84)	Reference
AG	108 (46.35)	158 (46.61)	1.94 (1.06-3.53)
GG	87 (37.34)	90 (26.55)	2.38 (1.24-4.55)
GG/AG	195 (83.69)	248 (73.15)	2.10 (1.18-3.71)
Log additive			1.49 (1.09-2.04)
rs13112099			
TT	38 (16.31)	91 (26.61)	Reference
GT	110 (47.21)	163 (47.66)	1.93 (1.06-3.52)
GG	85 (36.48)	88 (25.73)	2.35 (1.22-4.51)
GG/GT	195 (83.69)	251 (73.39)	2.07 (1.12-3.67)
Log additive			1.48 (1.08-2.03)
rs7686914			
TT	38 (16.45)	91 (26.84)	Reference
CT	109 (47.19)	160 (47.20)	1.94 (1.06-3.55)
CC	84 (36.36)	88 (25.96)	2.34 (1.22-4.50)
CC/CT	193 (83.55)	248 (73.81)	2.10 (1.17-3.70)
Log additive			1.48 (1.08-2.03)
rs7696472			
GG	38 (16.31)	92 (26.97)	Reference
AG	110 (47.21)	157 (46.04)	2.00 (1.10-3.63)
AA	85 (36.48)	90 (26.39)	2.30 (1.20-4.40)
AA/AG	195 (83.69)	249 (73.02)	2.10 (1.18-3.72)
Log additive			1.49 (1.06-2.00)
rs4148269			
CC	43 (18.45)	79 (23.23)	Reference
CA	72 (30.90)	160 (47.05)	0.81 (0.45-1.46)
AA	115 (49.35)	101 (29.70)	1.98 (1.02-3.85)
AA/CA	190 (81.54)	261 (76.76)	1.10 (0.63-1.90)
Log additive			1.45 (1.03-2.03)

Table 3 *ORs for the associations between *UGT2B15* and *UGT2B17* SNPs and PC (Continued)

rs3100			
TT	54 (23.78)	106 (31.08)	Reference
TC	68 (29.95)	140 (41.05)	1.04 (0.60-1.81)
CC	105 (46.25)	95 (27.85)	2.18 (1.19-3.99)
CC/TC	173 (76.21)	235 (68.91)	1.41 (0.86-2.31)
Log additive			1.46 (1.08-1.98)
Cis acting on UGT2B expression			
rs2168047			
AA	53 (22.84)	59 (17.45)	Reference
GA	112 (48.27)	169 (50.00)	0.86 (0.48-1.53)
GG	67 (28.87)	110 (32.54)	1.00 (0.52-1.88)
GG/GA	179 (77.15)	279 (82.54)	0.90 (0.52-1.57)
Log additive			1.01 (0.74-1.38)
rs6822259			
CC	3 (1.29)	12 (3.52)	Reference
CT	58 (25.00)	97 (28.44)	1.48 (0.36-6.02)
TT	171 (73.70)	232 (68.03)	1.34 (0.34-5.31)
TT/CT	229 (98.70)	329 (96.48)	1.39 (0.35-5.43)
Log additive			1.02 (0.68-1.53)
rs17147338			
CC	168 (72.1)	285 (83.58)	Reference
CT	55 (23.61)	51 (14.96)	1.68 (0.96-2.97)
TT	10 (4.29)	5 (1.47)	2.41 (0.42-13.94)
TT/CT	65 (27.9)	56 (16.42)	1.73 (1.00-3.00)
Log additive			1.65 (1.00-2.70)
UGT2B17			
rs7435827			
GG	53 (24.20)	106 (32.61)	Reference
GA	43 (19.63)	78 (24.00)	0.67 (0.35-1.30)
AA	123 (56.16)	141 (43.38)	0.90 (0.49-1.66)
AA/GA	166 (75.79)	219 (67.38)	0.80 (0.46-1.38)
Log additive			0.97 (0.71-1.36)
rs7686008			
AA	168 (71.79)	281 (82.4)	Reference
AT	34 (14.53)	32 (9.38)	1.40 (0.69-2.79)
TT	32 (13.68)	28 (8.21)	1.40 (0.66-2.96)
TT/AT	66 (28.21)	60 (17.6)	1.39 (0.79-2.44)
Log additive			1.21 (0.85-1.73)
rs7671342			
GG	37 (15.94)	56 (16.37)	Reference
GA	46 (19.83)	85 (24.85)	0.86 (0.43-1.73)
AA	149 (64.22)	201 (58.77)	1.32 (0.73-2.40)
AA/GA	195 (84.05)	286 (83.62)	1.17 (0.65-2.08)
Log additive			1.21 (0.91-1.61)

Table 3 *ORs for the associations between *UGT2B15* and *UGT2B17* SNPs and PC (Continued)

rs59678213			
CC	42 (19.44)	81 (25.63)	Reference
TC	46 (21.29)	74 (23.42)	0.84 (0.43-1.63)
TT	128 (59.26)	161 (50.94)	0.85 (0.45-1.59)
TT/TC	174 (80.55)	235 (74.37)	0.84 (0.47-1.50)
Log additive			0.92 (0.68-1.26)

*Adjusted for age, race and BMI.

in replicate. Based on the PicoGreen quantification, 10 ng of genomic DNA from each sample was used in the iPLEX assay for Sequenom-iPLEX Genotyping (Sequenom Inc., San Diego, CA). The Sequenom Mass Array (Sequenom Inc., San Diego, CA) was used and the assays for all SNPs were designed by Sequenom online assay tools (Assay Designer 4.0) at the David H. Murdock Research Institute (DHMRI) Genomics Laboratory (Kannapolis, NC). The data were analyzed by Sequenom-Typer 4.0. The Sequenom-iPLEX genotyping and analysis was validated with CEPH gDNA controls when performing the iPLEX assay and scanning on the MALDI-TOF Mass Spectrometer. At the time of this analysis, 585 samples were submitted and successfully produced good spectra for genotyping at a failure rate of <2.2% for the majority of SNPs. The Post-QC (Call Rate) of SNPs rs59678213 and rs7435827 was 92.7% and 94.7%, respectively. The assays included DHMRI control DNA (CEPH) on each plate in duplicate that were checked for concordance for each SNP. Sample duplicates were individually inspected for genotype consistency. Genotypes from duplicate samples were 100% concordant.

Statistical analysis

We examined whether genetic variants of *UGT2B17* and *UGT2B15* genes were associated with prostate cancer risk and whether these associations varied by race and prostate cancer grade. Low grade prostate cancer was defined as Gleason sum <8 and high-grade prostate cancer was defined as Gleason \geq 8. Potential confounders (age, height, and BMI) were normally distributed overall and were treated as continuous variables in modeling. Race was self-reported and categorized as African American, Caucasian and other (Native American and Latino). Family history of prostate cancer included maternal lineage (maternal uncle) or paternal lineage (father, brother or paternal uncle) (yes or no) and these combined. Data on tobacco use at the time of enrollment was also self-reported as yes or no.

Descriptive statistics (means, SD), and percentages for cases and controls were estimated using χ^2 tests for categorical variables, and Wilcoxon rank-sum test for continuous variables. Unconditional logistic regression was used to estimate the odd ratios (ORs) and 95% confidence

intervals (95% CI) for the association between genotypes and prostate cancer risk. Multinomial logistic regression models were used to explore whether associations between genotypes and prostate cancer risk varied by grade of prostate cancer at diagnosis, using controls as reference. Confounders adjusted for in all models were age, race, and BMI. All analyses were done using SAS version 9.3 (SAS Institute, Inc., Cary, NC).

Results

Table 2 describes the clinical characteristics of the study participants. Prostate cancer cases (n = 233) and controls (n = 342) were comparable in height (p = 0.31), however controls (mean BMI = 30.77, SD = 6.05) had slightly higher BMI than cases (mean BMI = 29.25, SD = 5.60, p = 0.002) and were slightly younger than cases (p = 0.005). African American men comprised 63% of the cases and 41% of the controls (p <0.0001). A family history of prostate cancer was reported by 14% of cases and 10% of the controls. (p = 0.16). Most cases and controls reported tobacco use (p = 0.43). Ninety-one percent of the cases had low-grade prostate cancer (Gleason sum < 8) vs. 9% of cases with high grade prostate cancer (Gleason sum \geq 8).

The functional variants of the *UGT2B15* and *UGT2B17* SNPs were assessed for associations with prostate cancer risk and summarized in Table 3. After adjusting for age, race and BMI, four *UGT2B15* SNPs, rs9994887, rs13112099, rs7686914 and rs7696472, were associated with increased risk of prostate cancer, when compared to the minor allele (Log additive model OR = 1.49, 95% CI = 1.09, 2.04; OR = 1.48, 95% CI = 1.08, 2.03, OR = 1.48, 95% CI = 1.08, 2.03, OR = 1.49, 95% CI = 1.06, 2.00, respectively). *UGT2B15* SNPs rs4148269 and rs3100, were also associated with increased risk for prostate cancer (Log additive model OR = 1.45, 95% CI = 1.03, 2.03; OR = 1.46, 95% CI = 1.08, 1.98, respectively). These data suggest that these associations were allele dose-dependent (Table 3). None of the *UGT2B17* SNPs studied were associated with prostate cancer risk, however the *UGT2B17* cis-acting SNP, rs17147338, showed borderline significance for increased risk of prostate cancer in an allele dose dependent fashion (OR = 1.65, 95% CI = 1.00, 2.70), after adjusting for age, race and BMI (Table 3). SNPs in high LD with *UGT2B15*^{D85Y}, rs9994887, rs13112099,

Table 4 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in low grade and high grade PC cases

SNP # Allele	Low gleason <8 n (%)	Adjusted OR (95% CI)	High gleason ≥8 n (%)	Adjusted OR* (95% CI)
UGT2B15				
rs1580083				
TT	0 (0)	Reference	2 (10.00)	Reference
TA	139 (65.88)	–	10 (50.00)	0.20 (0.02-2.42)
AA	72 (34.12)	–	8 (40.00)	0.33 (0.02-4.36)
AA/TA	211 (100.0)	–	18 (90.00)	0.13 (0.02-0.74)
Log additive		–		3.20 (0.30-33.45)
rs1960773				
TT	0 (0)	Reference	1 (5.26)	Reference
GT	132 (63.16)	–	11 (57.89)	–
GG	77 (36.84)	–	7 (36.84)	–
GG/GT	209 (100.0)	–	18 (94.73)	–
Log additive		–		–
rs9994887				
AA	32 (15.17)	Reference	5 (25.00)	Reference
AG	101 (47.87)	2.13 (1.13-4.00)	7 (35.00)	0.86 (0.19-3.80)
GG	78 (36.97)	2.53 (1.30-4.99)	8 (40.00)	1.27 (0.26-6.17)
GG/AG	179 (84.83)	2.27 (1.24-4.14)	15 (75.00)	1.00 (0.25-3.90)
Log additive		1.94 (1.06-3.53)		2.34 (1.22-4.49)
rs13112099				
TT	32 (15.16)	Reference	5 (25.00)	Reference
GT	103 (48.81)	2.12 (1.13-3.98)	7 (35.00)	0.84 (0.19-3.71)
GG	76 (36.01)	2.50 (1.26-4.93)	8 (40.00)	1.30 (0.26-6.28)
GG/GT	179 (84.83)	2.25 (1.23-4.10)	15 (75.00)	1.00 (0.25-3.87)
Log additive		1.93 (1.06-3.52)		2.31 (1.20-4.44)
rs7686914				
TT	32 (15.23)	Reference	7 (36.83)	Reference
CT	102 (48.57)	2.14 (1.14-4.02)	7 (36.84)	0.86 (0.19-3.78)
CC	76 (36.19)	2.50 (1.26-4.92)	5 (26.32)	1.30 (0.26-6.30)
CC/CT	178 (84.76)	2.25 (1.23-4.13)	12 (63.16)	1.00 (0.26-3.92)
Log additive		1.94 (1.06-3.54)		2.31 (1.20-4.44)
rs7696472				
AA	32 (15.17)	Reference	8 (40.00)	Reference
AG	103 (48.82)	2.20 (1.16-4.12)	7 (35.00)	0.86 (0.19-3.82)
GG	76 (36.02)	2.43 (1.23-4.81)	5 (25.00)	1.26 (0.26-6.11)
GG/AG	179 (84.83)	2.30 (1.25-4.16)	12 (60.00)	1.00 (0.26-3.92)
Log additive		1.99 (1.10-3.63)		2.26 (1.18-4.33)
rs4148269				
CC	38 (18.18)	Reference	5 (26.32)	Reference
CA	66 (31.58)	0.76 (0.42-1.40)	5 (26.32)	2.16 (0.23-20.26)
AA	105 (50.24)	1.70 (0.86-3.36)	9 (47.36)	13.55 (1.34-136.99)
AA/CA	171 (81.81)	1.00 (0.56-1.74)	14 (73.68)	3.94 (0.47-2.58)
Log additive		0.81 (0.45-1.47)		1.96 (1.01-3.82)

Table 4 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in low grade and high grade PC cases (Continued)

rs3100				
TT	46 (22.33)	Reference	7 (36.84)	Reference
TC	64 (31.07)	1.04 (0.60-1.83)	4 (21.05)	1.10 (0.17-6.86)
CC	96 (46.60)	1.96 (1.06-3.63)	8 (42.10)	8.22 (1.31-51.60)
CC/TC	160 (77.66)	1.34 (0.81-2.22)	12 (63.16)	2.42 (0.50-11.83)
Log additive		1.04 (0.60-1.81)		2.16 (1.18-3.95)
rs2168047				
AA	49 (23.22)	Reference	3 (15.79)	Reference
GA	99 (46.92)	0.78 (0.43-1.42)	12 (63.16)	2.61 (0.30-22.38)
GG	63 (29.86)	0.96 (0.50-1.84)	4 (21.05)	1.92 (0.18-20.07)
GG/GA	162 (76.77)	0.84 (0.48-1.48)	16 (84.21)	2.38 (0.30-19.86)
Log additive		0.85 (0.51-1.40)		1.01 (0.53-1.91)
rs6822259				
CC	3 (1.43)	Reference	0 (0)	Reference
CT	50 (23.81)	1.25 (0.30-5.10)	7 (35.00)	-
TT	157 (74.76)	1.27 (0.32-5.03)	13 (65.00)	-
TT/CT	207 (98.57)	1.26 (0.32-4.95)	20 (100.00)	-
Log additive		1.11 (0.68-1.79)		-
rs17147338				
CC	154 (72.99)	Reference	12 (60.00)	Reference
CT	48 (22.75)	1.64 (0.92-2.93)	7 (35.00)	2.78 (0.65-11.96)
TT	9 (4.27)	1.92 (0.30-12.18)	1 (5.00)	12.86 (0.91-181.95)
TT/CT	57 (27.01)	1.67 (0.94-2.91)	8 (40.00)	3.41 (0.89-13.08)
Log additive		1.70 (1.00-3.01)		2.44 (0.42-12.17)
UGT2B17				
rs7435827				
GG	50 (25.00)	Reference	3 (16.67)	Reference
GA	38 (19.00)	0.67 (0.34-1.31)	4 (22.22)	0.73 (0.11-4.72)
AA	112 (56.00)	0.87 (0.46-1.63)	11 (61.11)	1.33 (0.26-6.84)
AA/GA	150 (75.00)	0.78 (0.44-1.37)	15 (83.33)	1.03 (0.23-4.65)
Log additive		0.67 (0.35-1.32)		0.90 (0.49-1.66)
rs7686008				
AA	154 (72.99)	Reference	12 (60.00)	Reference
AT	29 (13.74)	1.25 (0.61-2.58)	4 (20.00)	5.42 (1.05-27.96)
TT	28 (13.27)	1.30 (0.60-2.80)	4 (20.00)	5.05 (0.72-35.66)
TT/AT	57 (27.01)	1.27 (0.71-2.28)	8 (40.00)	5.30 (1.19-23.55)
Log additive		1.41 (0.70-2.84)		1.42 (0.67-3.01)
rs7671342				
GG	34 (16.19)	Reference	3 (14.28)	Reference
GA	43 (20.48)	0.89 (0.44-1.81)	4 (19.05)	0.61 (0.08-4.60)
AA	133 (63.33)	1.31 (0.71-2.41)	14 (66.67)	1.28 (0.26-6.35)
AA/GA	176 (83.81)	1.17 (0.64-2.11)	18 (85.71)	1.05 (0.22-5.04)
Log additive		0.86 (0.43-1.73)		1.30 (0.72-2.36)

Table 4 *ORs for the associations between *UGT2B15* and *UGT2B17* SNPs and PC in low grade and high grade PC cases (Continued)

rs59678213				
CC	40 (20.20)	Reference	2 (11.76)	Reference
TC	41 (20.71)	0.99 (0.54-1.81)	4 (23.53)	2.77 (0.27-28.17)
TT	117 (59.09)	0.76 (0.40-1.45)	11 (64.71)	3.60 (0.38-33.75)
TT/TC	158 (79.79)	0.76 (0.42-1.38)	15 (88.23)	3.21 (0.37-27.47)
Log additive		1.02 (0.56-1.82)		1.18 (0.63-2.21)

*Adjusted for age, race and BMI.

rs7686914, and rs796472 [34] were associated with increased risk of prostate cancer in an allele dose-dependent manner for both high-grade (OR = 2.34, 95% CI = 1.22, 4.49; OR = 2.31, 95% CI = 1.20, 4.44; OR = 2.31, 95% CI = 1.20, 4.44; OR = 2.26, 95% CI = 1.18, 4.33, respectively) and low-grade prostate cancer lesions (OR = 1.94, 95% CI = 1.06, 3.53; OR = 1.93, 95% CI = 1.06, 3.52; OR = 1.94, 95% CI = 1.06, 3.53; OR = 1.99, 95% CI = 1.10, 3.63, respectively) after adjusting for age, race, and BMI (Table 4). Intriguingly, SNPs rs4148269 and rs3100 were associated with increased PC risk in high grade lesions only (OR = 1.96, 95% CI = 1.01, 3.82; OR = 2.16, 95% CI = 1.18, 3.95).

Restricting analyses by race/ethnicity, and after adjusting for age and BMI, further revealed that these associations were present in African American men (rs9994887, OR = 1.66, 95% CI = 1.05, 2.63; rs13112099, OR = 1.66, 95% CI = 1.03, 2.63; rs7686914, OR = 1.64, 95% CI = 1.03, 2.63; rs7696472, OR = 1.64, 95% CI = 1.03, 2.63; rs4148269, OR = 2.04, 95% CI = 1.19, 3.44; and rs3100, OR = 1.89, 95% CI = 1.22, 2.94) (Table 5). However, the interaction terms for these SNPs and race were not statistically significant ($p > 0.4$) for all six SNPs. For both groups, carrying the *UGT2B17* or *cis*-acting SNPs was not associated with prostate cancer risk (Table 5).

To investigate the extent to which these SNPs were associated in our subjects we calculated correlation coefficients among the controls as shown in Table 6. The r^2 values for the *UGT2B15* variants rs1580083, rs1960773, rs13112099, rs7686914, rs7696472 and rs9994887 ranged from 0.62 to 0.99/1.00 ($p < 0.0001$). *UGT2B15* variants rs4148269 and rs3100 were also strongly correlated ($r^2 = 0.85$, $p < 0.0001$). Including both SNPs into the same regression model to evaluate whether one SNP would have a stronger association with PC risk did not yield additional insights. Notably, these two SNPs showed no correlation with the other SNPs that were highly associated with each other. *UGT2B17* SNP rs7435827 was moderately correlated with *UGT2B15* SNP rs2168047 ($r^2 = 0.36$, $p < 0.0001$) and *UGT2B17* SNP rs7671342 ($r^2 = 0.32$, $p < 0.0001$), and strongly correlated with *UGT2B17* SNP rs59678213

($r^2 = 0.83$, $p < 0.0001$); however these SNPs showed no association with prostate cancer risk. *UGT2B17* SNP rs59678213 was inversely associated with *UGT2B17* SNPs rs2168047 ($r^2 = -0.47$, $p < 0.0001$), rs7686008 ($r^2 = -0.29$, $p < 0.0001$) and rs7671342 ($r^2 = -0.49$, $p < 0.0001$). No correlations were observed for the *cis*-acting *UGT2B* SNPs that were identified through the recent *UGT2B* SNPs discovery study [38]. All SNPs that showed associations with prostate cancer risk were in Hardy-Weinberg equilibrium in control samples, except for *UGT2B15* SNP rs3100.

Discussion and conclusion

In this study we examined associations between functional SNPs of the *UDP-glucuronosyltransferase 2B (UGT2B)* genes and prostate cancer risk. After adjusting for age and BMI, we found that two *UGT2B15* SNPs, rs4148269 and rs3100, were associated with a two-fold increase risk of prostate cancer and the association was more apparent in African American men. In addition, SNPs rs9994887, rs13112099, rs7686914 and rs7696472 were also associated with increased risk of prostate cancer. These associations persisted either in low or high-grade prostate cancer lesions for SNPs rs9994887, rs13112099, rs7686914, and rs7696472. However, SNPs rs4148269 and rs3100 were only associated with increased risk of prostate cancer in high-grade prostate cancer lesions. These findings are novel and support the hypothesis that these SNPs may affect UDP-glucuronosyltransferase enzyme function, presumably by increasing the efficiency of androgen metabolite clearance compared to enzyme products of the *UGT2B* wild type genotype, as has been shown for *UGT2B15* SNP rs1902023 [21].

Associations between functional SNPs of the *UGT2B15* and *UGT2B17* genes and prostate cancer risk have been previously examined and have rendered conflicting results [22-32]. Discrepancies could be due in part to racial/ethnic differences in the populations studied but also to sample size and allele dosage. Comparison of two studies with different sample sizes revealed contradictory results: no associations between SNP *UGT2B15*^{D85Y} and prostate cancer risk were found in a study with a large sample size [9], whereas a study with a smaller sample size found an increased risk of prostate cancer associated with the

Table 5 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in African American and Caucasian men

SNP # Allele	African American			Caucasian		
	Cases n (%)	Controls n (%)	Adjusted OR (95% CI)*	Cases n (%)	Controls n (%)	Adjusted OR (95% CI)*
UGT2B15						
rs1580083						
TT	0 (0)	1 (0.72)	Reference	2 (2.30)	4 (20.9)	Reference
TA	86 (58.90)	94 (68.12)	—	64 (73.56)	155 (77.11)	1.22 (0.10-14.43)
AA	60 (41.10)	43 (31.16)	—	21 (24.14)	42 (1.99)	1.36 (0.11-16.96)
AA/TA	146 (100.0)	137 (99.27)	—	85 (97.70)	159 (79.1)	1.25 (0.11-14.73)
Log additive			—			1.12 (0.58-2.17)
rs1960773						
TT	0 (0)	2 (1.45)	Reference	1 (1.16)	3 (23.38)	Reference
GT	82 (56.94)	93 (67.39)	—	62 (72.09)	151 (75.12)	—
GG	62 (43.06)	43 (31.16)	—	23 (26.74)	47 (1.49)	—
GG/GT	144 (100.0)	136 (98.55)	—	85 (98.83)	198 (76.62)	—
Log additive			—			—
rs9994887						
AA	16 (10.96)	28 (20.44)	Reference	22 (25.29)	63 (31.50)	Reference
AG	65 (44.52)	63 (45.99)	1.92 (0.72-5.10)	43 (49.43)	93 (46.50)	1.93 (0.90-4.14)
GG	65 (44.52)	46 (33.58)	2.96 (1.09-8.04)	22 (25.29)	44 (22.00)	1.87 (0.77-4.54)
GG/AG	130 (89.04)	109 (79.56)	2.34 (0.93-5.88)	65 (74.71)	137 (68.50)	1.91 (0.92-3.96)
Log additive			1.66 (1.05-2.63)			1.35 (0.88-2.08)
rs13112099						
TT	16 (10.96)	28 (20.00)	Reference	22 (25.29)	63 (31.18)	Reference
GT	67 (45.89)	68 (48.57)	1.96 (0.74-5.20)	43 (49.43)	95 (47.03)	1.88 (0.88-4.05)
GG	63 (43.15)	44 (31.43)	2.94 (1.07-8.05)	22 (25.29)	44 (21.78)	1.87 (0.77-4.54)
GG/GT	130 (89.04)	112 (80.00)	2.34 (0.93-5.88)	65 (74.71)	139 (68.81)	1.88 (0.91-3.91)
Log additive			1.66 (1.03-2.63)			1.35 (0.88-2.08)
rs7686914						
TT	16 (11.03)	28 (20.14)	Reference	22 (25.58)	63 (31.50)	Reference
CT	67 (46.21)	67 (48.20)	2.00 (0.75-5.31)	42 (48.84)	93 (46.50)	1.88 (0.87-4.05)
CC	62 (42.75)	44 (31.65)	2.94 (1.07-8.05)	22 (25.58)	44 (22.00)	1.87 (0.77-4.54)
CC/CT	129 (88.96)	111 (79.86)	2.37 (0.94-5.96)	64 (74.42)	137 (68.50)	1.88 (0.91-3.91)
Log additive			1.64 (1.03-2.63)			1.35 (0.88-2.08)
rs7696472						
GG	16 (10.96)	29 (20.70)	Reference	22 (25.29)	63 (31.66)	Reference
AG	67 (45.89)	67 (47.86)	1.96 (0.74-5.20)	43 (49.43)	90 (45.23)	2.01 (0.93-4.32)
AA	63 (43.15)	44 (31.43)	2.94 (1.07-8.05)	22 (25.29)	46 (23.12)	1.77 (0.73-4.27)
AA/AG	130 (89.04)	111 (79.28)	2.34 (0.93-5.88)	65 (74.71)	136 (68.34)	1.93 (0.93-4.04)
Log additive			1.64 (1.03-2.63)			1.31 (0.86-2.00)
rs4148269						
CC	9 (6.25)	11 (7.86)	Reference	34 (39.53)	68 (34.00)	Reference
CA	34 (23.61)	58 (41.43)	0.73 (0.20-2.70)	38 (44.19)	102 (51.00)	0.89 (0.46-1.73)
AA	101 (70.14)	71 (50.71)	2.34 (0.67-7.83)	14 (16.28)	30 (15.00)	1.46 (0.57-3.77)
AA/CA	135 (93.75)	129 (92.14)	1.65 (0.51-5.34)	52 (60.46)	132 (66.00)	0.99 (0.53-1.85)

Table 5 *ORs for the associations between UGT2B15 and UGT2B17 SNPs and PC in African American and Caucasian men (Continued)

Log additive			2.04 (1.19-3.44)			1.12 (0.71-1.75)
rs3100						
TT	18 (12.86)	32 (23.02)	Reference	36 (41.38)	74 (36.63)	Reference
TC	31 (22.14)	42 (30.22)	1.57 (0.54-4.55)	37 (42.53)	98 (48.51)	0.91 (0.47-1.72)
CC	91 (65.00)	65 (46.76)	3.36 (1.36-8.30)	14 (16.09)	30 (14.85)	1.48 (0.58-3.78)
CC/TC	122 (87.14)	107 (76.97)	2.75 (1.15-6.58)	51 (58.62)	128 (63.36)	1.00 (0.54-1.84)
Log additive			1.89 (1.22-2.94)			1.12 (0.72-1.75)
Cis acting on UGT2B expression						
rs2168047						
AA	42 (28.97)	36 (26.09)	Reference	11 (12.64)	23 (11.50)	Reference
GA	69 (47.59)	65 (47.10)	0.83 (0.39-1.75)	43 (49.43)	104 (52.00)	0.92 (0.35-2.42)
GG	34 (23.44)	37 (26.81)	0.91 (0.37-2.21)	33 (37.94)	73 (36.50)	1.07 (0.39-2.93)
GG/GA	103 (71.03)	102 (73.91)	0.85 (0.42-1.72)	76 (87.35)	177 (88.50)	0.98 (0.38-2.48)
Log additive			0.94 (0.61-1.47)			1.07 (0.67-1.72)
rs6822259						
CC	1 (0.69)	4 (2.86)	Reference	2 (2.30)	8 (3.98)	Reference
CT	25 (17.24)	38 (27.14)	0.61 (0.03-10.56)	33 (37.93)	59 (29.35)	1.60 (0.86-2.96)
TT	119 (82.07)	98 (70.00)	0.91 (0.05-14.99)	52 (59.77)	134 (66.67)	0.70 (0.14-3.54)
TT/CT	144 (99.31)	136 (97.14)	0.83(0.05-13.61)	85 (97.70)	193 (96.01)	1.47 (0.81-2.67)
Log additive			1.34 (0.68-2.77)			1.23 (0.75-2.03)
rs17147338						
TT	91 (62.33)	100 (71.43)	Reference	77 (88.51)	0 (0)	Reference
CT	46 (31.51)	35 (25.00)	1.72 (0.84-3.54)	9 (10.34)	16 (7.96)	-
CC	9 (6.16)	5 (3.57)	1.51 (0.23-9.88)	1 (1.15)	185 (92.04)	-
CC/CT	55 (37.67)	40 (28.57)	1.70 (0.85-3.40)	10 (11.49)	16 (7.96)	-
Log additive			1.53 (0.84-2.82)			-
UGT2B17						
rs7435827						
GG	13 (9.35)	13 (9.56)	Reference	40 (50.00)	93 (49.21)	Reference
GA	22 (15.83)	27 (19.85)	0.47 (0.12-1.92)	21 (26.25)	51 (26.98)	0.78 (0.37-1.66)
AA	104 (74.82)	96 (70.59)	0.80 (0.24-2.68)	19 (23.75)	45 (23.81)	0.86 (0.40-1.85)
AA/GA	126 (90.65)	123 (90.44)	0.72 (0.22-2.41)	40 (50.00)	96 (50.79)	0.82 (0.44-1.52)
Log additive			1.08 (0.64-1.85)			1.08 (0.75-1.59)
rs7686008						
AA	83 (56.85)	92 (66.19)	Reference	84 (96.55)	189 (93.56)	Reference
AT	32 (21.92)	25 (17.99)	1.65 (0.74-3.69)	2 (2.3)	7 (3.47)	0.70 (0.13-3.71)
TT	31 (21.23)	22 (15.83)	1.51 (0.67-3.44)	1 (1.15)	6 (2.97)	0.99 (0.10-10.04)
TT/AT	63 (43.15)	47 (33.81)	1.58 (0.83-3.01)	3 (3.45)	13 (6.44)	0.78 (0.20-3.08)
Log additive			1.28 (0.86-1.90)			0.88 (0.33-2.36)
rs7671342						
GG	22 (15.07)	23 (16.43)	Reference	15 (17.44)	33 (16.34)	Reference
GA	25 (17.12)	35 (25.00)	0.66 (0.24-1.88)	21 (24.42)	50 (24.75)	1.06 (0.42-2.67)
AA	99 (67.81)	82 (58.57)	1.51 (0.63-3.64)	50 (58.14)	119 (58.91)	1.15 (0.51-2.59)
AA/GA	124 (84.93)	117 (83.57)	1.21 (0.52-2.84)	71 (82.55)	169 (83.66)	1.12 (0.51-2.46)

Table 5 *ORs for the associations between *UGT2B15* and *UGT2B17* SNPs and PC in African American and Caucasian men (Continued)

Log additive			1.36 (0.90-2.08)	1.07 (0.73-1.59)		
rs59678213						
CC	10 (7.35)	8 (5.97)	Reference	32 (40.00)	73 (40.11)	Reference
TC	19 (13.97)	24 (17.91)	0.45 (0.10-2.00)	27 (33.75)	50 (27.47)	1.04 (0.49-2.20)
TT	107 (78.68)	102 (76.12)	0.65 (0.18-2.41)	21 (26.25)	59 (32.42)	0.80 (0.37-1.71)
TT/TC	126 (92.65)	126 (94.02)	0.62 (0.17-2.24)	48 (60.00)	109 (59.89)	0.91 (0.48-1.73)
Log additive			0.99 (0.64-1.69)	1.11 (0.76-1.61)		

*Adjusted for age and BMI.

UGT2B15^{D85Y} variant in Caucasian subjects [32]. In reference to allele dosage, we previously concluded [33], concordant with previous reports [31,32,39], that homozygous carriers of the dominant *UGT2B15*^{D85Y} (G) allele missense polymorphism, (rs1902023), had an almost three-fold higher risk of prostate cancer. Our current results further confirm that associations with *UGT2B15* polymorphisms are allele dose-dependent and may also be dependent on race/ethnicity. Furthermore, our study includes a large and multiethnic sample size in comparison to previous reports.

Some of our stratified analyses revealed that *UGT2B15* wild type alleles were significantly associated with increased risk of prostate cancer in African American men, but not in Caucasian men, suggesting that the wild type genotype may confer protection against prostate cancer in Caucasian men. While these findings require replication in larger studies, we provide new evidence that wild type genotypes for the *UGT2B15* gene more frequently found in African American men may increase the risk of prostate cancer, and thus may contribute to the present racial/ethnic disparities seen in prostate cancer incidence. Few studies have assessed the association of *UGT2B* genes with prostate cancer risk in African Americans. Park et al. [25] were one of the first to report that associations between *UGT2B17* polymorphisms and increased risk of prostate cancer were linked to race/ethnicity; they showed that Caucasian men carrying a *UGT2B17* deletion polymorphism had a two-fold increased risk of prostate cancer, but not Black men who carry the same deletion, compared to non-carriers [25]. Subsequent work supported these findings [22,26], which were further confirmed by others [23,24]. Our results show no significant associations of *UGT2B17* polymorphisms with prostate cancer risk in neither Caucasian nor African American men. Our findings that *UGT2B17* SNP rs59678213 was not associated with prostate cancer risk are consistent with those of others [22,24].

Four of the *UGT2B15* SNPs that conferred prostate cancer risk in this study are among seven SNPs (rs1580083, rs1960773, rs9994887, rs13112099, rs7686914, rs7696472,

and rs1120265 [not in study]) that are in high linkage disequilibrium (LD) with *UGT2B15*^{D85Y} SNP rs1902023 [34]. The phenotype of the variations, established with reporter gene assays in the liver cancer cell line HepG2, showed that transcriptional activity was higher for constructs containing the major alleles when compared to constructs containing the minor alleles. When a construct with the minor allele of rs9994887 was transfected into a prostate cancer cell line, LNCaP, transcriptional activity was decreased by approximately 14%, compared to constructs containing the major allele [34], which suggested that rs9994887 may influence gene expression in the prostate [34]. Further experiments would have to be done to determine the impact of these variants on the kinetics and efficacy of UGT2B enzymes. Interestingly, the other three SNPs that showed associations with increased prostate cancer risk, rs13112099, rs7686914, and rs7696472 were highly correlated with rs9994887 ($r^2 = 0.99, 0.99, \text{ and } 0.97$, respectively). In addition, the three SNPs are all located upstream of rs9994887 (-1139 bp relative to translation start) while the other two SNPs are located downstream. While the impact of these variants on UGT2B15 enzyme kinetics has not been reported, the associations suggest that the phenotype of the enzyme may be similar to that of the *UGT2B15*^{85Y} variant or rs1902023 [19]. SNPs rs4148269 and rs3100 also demonstrated strong associations with decreased risk of PC, but did not show any correlation with the promoter SNPs in this study population. SNP rs4148269 has been characterized as a T523K amino acid substitution [40], however a comprehensive analysis of the enzyme phenotype has not been reported. This suggests that rs3100, which is highly correlated ($r^2 = 0.85$) with rs4148269, may be important in the etiology of PC. Results from reporter gene assays showed that the major allele of rs3100 is associated with significantly higher gene expression in LNCaP cells when compared to constructs made with the minor allele [36].

The lack of association observed for the *UGT2B17* SNPs and PC risk was unexpected, as previous reports suggested that the UGT2B17 enzyme plays a major role in testosterone glucuronidation [20]. However results from a recent

Table 6 Spearman correlation coefficients and p values for UGT2B15 and UGT2B17 SNPs

	rs1580083	rs1960073	rs9994887	rs13112099	rs7686914	rs7696472	rs4148269	rs3100	rs2168047	rs6822259	rs17147338	rs7435827	rs7686008	rs7671342
rs1580083	1.000	0.894	0.625	0.637	0.638	0.625	0.002	0.000	0.000	0.000	0.002	0.001	0.000	0.002
		<.0001	<.0001	<.0001	<.0001	<.0001	0.458	0.780	0.749	0.873	0.366	0.527	0.720	0.414
rs1960073	0.894	1.000	0.631	0.650	0.645	0.631	0.001	0.000	0.001	0.001	0.002	0.000	0.000	0.003
	<.0001		<.0001	<.0001	<.0001	<.0001	0.669	0.931	0.634	0.614	0.366	0.946	0.686	0.284
rs9994887	0.625	0.631	1.000	0.989	0.989	0.973	0.000	0.000	0.002	0.000	0.003	0.010	0.001	0.006
	<.0001	<.0001		<.0001	<.0001	<.0001	0.685	0.776	0.384	0.894	0.296	0.069	0.549	0.145
rs13112099	0.637	0.650	0.989	1.000	1.000	0.984	0.001	0.070	0.002	0.000	0.004	0.009	0.001	0.005
	<.0001	<.0001	<.0001		<.0001	<.0001	0.033	0.627	0.461	0.970	0.263	0.093	0.510	0.176
rs7686914	0.638	0.645	0.989	1.000	1.000	0.984	0.001	0.001	0.002	0.000	0.004	0.009	0.001	0.005
	<.0001	<.0001	<.0001	<.0001		<.0001	0.033	0.627	0.462	0.970	0.264	0.094	0.510	0.177
rs7696472	0.625	0.631	0.973	0.984	0.984	1.000	0.002	0.002	0.001	0.000	0.003	0.007	0.001	0.006
	<.0001	<.0001	<.0001	<.0001	<.0001		0.044	0.443	0.523	0.961	0.282	0.139	0.619	0.161
rs4148269	0.002	0.001	0.000	0.001	0.001	0.002	1.000	0.849	0.000	0.000	0.007	0.046	0.059	0.021
	0.458	0.669	0.685	0.550	0.550	0.4217		<.0001	0.854	0.753	0.122	0.0001	<.0001	0.008
rs3100	0.000	0.000	0.000	0.070	0.001	0.002	0.849	1.000	0.003	0.001	0.002	0.018	0.021	0.015
	0.780	0.931	0.776	0.627	0.627	0.443	<.0001		0.332	0.530	0.362	0.016	0.007	0.023
rs2168047	0.000	0.001	0.002	0.002	0.002	0.001	0.000	0.003	1.000	0.007	0.001	0.356	0.043	0.139
	0.749	0.634	0.384	0.461	0.462	0.523	0.854	0.332		0.135	0.549	<.0001	0.0001	<.0001
rs6822259	0.000	0.001	0.000	0.000	0.000	0.000	0.000	0.001	0.007	1.000	0.023	0.004	0.006	0.000
	0.873	0.614	0.894	0.970	0.970	0.961	0.753	0.530	0.135		0.005	0.279	0.170	0.825
rs17147338	0.002	0.002	0.003	0.004	0.004	0.003	0.007	0.002	0.001	0.023	1.000	0.005	0.000	0.000
	0.366	0.366	0.295	0.263	0.264	0.282	0.122	0.362	0.549	0.005		0.223	0.895	0.873
rs7435827	0.001	0.000	0.010	0.009	0.009	0.007	0.046	0.018	0.356	0.004	0.005	1.000	0.162	0.318
	0.527	0.946	0.069	0.093	0.093	0.139	0.0001	0.016	<.0001	0.279	0.223		<.0001	<.0001
rs7686008	0.000	0.000	0.001	0.001	0.001	0.001	0.059	0.021	0.043	0.006	0.000	0.162	1.000	0.047
	0.720	0.686	0.549	0.510	0.510	0.619	<.0001	0.007	0.0001	0.170	0.895	<.0001		<.0001
rs7671342	0.002	0.003	0.006	0.005	0.005	0.006	0.021	0.015	0.139	0.000	0.000	0.318	0.047	1.000
	0.414	0.284	0.145	0.176	0.177	0.161	0.008	0.023	<.0001	0.825	0.873	<.0001	<.0001	
rs59678213	0.032	-0.001	0.078	0.071	0.070	0.058	0.116	0.045	-0.473	0.086	-0.077	0.830	-0.494	1.000
	0.577	0.985	0.170	0.211	0.213	0.303	0.034	0.42	<.00001	0.217	0.168	<.00001	<.0001	

report comparing UGT2B17 and UGT2B15 mRNA and protein expression, suggest that *UGT2B15* may be negatively regulated in naïve and castration-resistant tumors while undetectable in lymph node metastases [41]. More *in vitro* analyses are required to understand the functional impact of these genetic variations. Nonetheless this is the first time these SNPs are reported in relation to prostate cancer risk.

The main limitation of this study is the sample size which limited our ability to simultaneously examine race/ethnicity in the associations with SNPs and prostate cancer grade. The low numbers of Caucasians may have limited our ability to detect significant associations within this group given that they were less likely to present a high grade PC tumor. The small sample size could also have been a contributing factor in the lack of significance for the cross-product term for the SNPs and race, however race/ethnicity was self-reported and we did not measure ancestral markers, which could indicate the percentage of African American ancestry of each subject. Also, we cannot exclude the possibility of potential confounding due to differences in MAFs between races. Nonetheless our study was conducted at the DVAMC which provides medical care for all former military personnel. This type of setting has important advantages. The Veterans Affairs Medical Centers (VAMC) are considered an equal-access health care settings that may control for health care availability among various U.S. ethnicities [42]. Moreover, the VAMCs provide a setting for PC case-control studies as this is the leading cancer reported in Veterans Affairs Central Registry (VACCR) [43].

Despite these limitations, in the current case-control study of African American and Caucasian men, we observed elevated risk of prostate cancer in African American men who carry the wild type of the functional *UGT2B15* gene variants. Future studies with larger sample sizes are needed to confirm these findings.

Competing interests

No potential conflict of interest were disclosed.

Authors' contributions

DJG conceived and designed the experiments. MM and SJF provided the samples. ACV, CT, DJG and CH analyzed and interpreted the data. SJF, RMR and JMS contributed in the writing of the manuscript. ACV, CT, DJG and CH wrote the manuscript. All authors have read and approved the final manuscript.

Acknowledgements

We would like to thank Gary Bradwin of the Children's Hospital of Boston; Meredith Bostrom of the David H. Murdock Research Institute, Kannapolis, NC; Shannon Oliver of North Carolina Central University and Alexis Gaines and Katie Shuler of Duke University for assistance.

Grant support

Department of Defense PC060233, NIH P20 MD000175, S06-GM008049-33, Department of Veterans Affairs, and the AUA Foundation/Astellas Rising Star in Urology, National Institutes of Health R01CA142983, R01CA142983-02S1, and R21ES021838-01A1.

Author details

¹Department of Obstetrics and Gynecology, and Program of Cancer Detection, Prevention and Control, Duke University School of Medicine, Durham, NC 27710, USA. ²Department of Biology and Cancer Research Program, JLC-Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA. ³Department of Community and Family Medicine and Program of Cancer Detection, Prevention and Control, Duke University Medical Center, Durham, NC 27705, USA. ⁴Department of Surgery, Division of Urology, Duke University Medical Center, Durham, NC 27710, USA. ⁵Department of Surgery, Durham VA Medical Center, Durham, NC 27705, USA. ⁶Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA. ⁷Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

Received: 25 February 2013 Accepted: 20 November 2013

Published: 22 November 2013

References

1. Siegel R, Naishadham D, Jemal A: **Cancer statistics, 2012.** *CA Cancer J Clin* 2012, **62**:10–29.
2. Brawley OW, Jani AB, Master V: **Prostate cancer and race.** *Curr Probl Cancer* 2007, **31**:211–225.
3. Resnick MJ, Canter DJ, Guzzo TJ, Brucker BM, Bergey M, Sonnand SS: **Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?** *Urology* 2009, **73**:620–623.
4. Robbins AS, Yin D, Parikh-Patel A: **Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004.** *Am J Epidemiol* 2007, **166**:71–78.
5. Gilligan T: **Social disparities and prostate cancer: mapping the gaps in our knowledge.** *Cancer Causes Control* 2005, **16**:45–53.
6. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W: *SEER Cancer Statistics Review.* Bethesda: National Cancer Institute; 1975–2008.
7. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, Thun M: **Cancer disparities by race/ethnicity and socioeconomic status.** *CA Cancer J Clin* 2004, **54**:78–93.
8. Jemal A, Siegel R, Xu J, Ward E: **Cancer Statistics.** *CA Cancer J Clin* 2010, **60**:277–300.
9. Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN: **Spatial patterns of localized-stage prostate cancer incidence among white and black men in southeastern United States, 1999–2001.** *Cancer Epidemiol Biomarkers Prev* 2010, **19**:1460–1467.
10. Major JM, Oliver M, Doubeni CA, Hollenbeck AR, Graubard BI, Sinha R: **Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study.** *Cancer Causes Control* 2012, **23**:1185–1191.
11. Ricke EA, Williams K, Lee Y-I, Couto S, Wang Y, Hayward SW, Cunha GR, Ricke WA: **Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.** *Carcinogenesis* 2012, **33**:1391–1398.
12. Tang L, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Kristal AR, Platz EA, Neuhaus ML, Stanczyk FZ, Reichard JKV, Santella RM, Hsing A, Hoque A, Lippman SM, Thompson IM, Ambrosone CB: **Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.** *Carcinogenesis* 2011, **32**:1500–1506.
13. Vasaitis TS, Bruno RD, Njar VCO: **CYP17 inhibitors for prostate cancer therapy.** *J Steroid Biochem Mol Biol* 2011, **125**:23–31.
14. Ritter JK: **Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions.** *Chem Biol Interact* 2000, **129**:171–193.
15. Belanger A, Piletier G, Labrie F, Barbier O, Chouinard S: **Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans.** *Trends Endocrinol Metabol* 2001, **14**:473–479.
16. Chouinard S, Barbier O, Belanger A: **UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.** *J Biol Chem* 2007, **282**:33466–33474.
17. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A: **Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.** *Endocrinology* 2001, **142**:778–787.
18. Wilson W III, De Villena FP-M, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, Gilmore RC, Valladeras IC, Wright CC, Treadgill DW, Grant DJ:

- Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. *Genomics* 2004, **84**:707–714.
19. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW: **Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.** *Pharmacogenetics* 1997, **7**:317–325.
 20. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Ohlsson C, Roh HK, Carlstrom K, Rane A: **Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.** *J Clin Endocrinol Metab* 2006, **91**:687–693.
 21. Chouinard S, Yueh MF, Tukey RH, Giton F, Fiet J, Pelletier G, Barbier O, Belanger A: **Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling.** *J Steroid Biochem Mol Biol* 2008, **109**:247–253.
 22. Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P: **The UGT2B17 gene deletion polymorphism and risk of prostate cancer A case-control study in Caucasians.** *Cancer Detect Prev* 2007, **31**:310–315.
 23. Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L: **Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.** *Pharmacogenomics J* 2008, **8**:147–151.
 24. Olsson M, Lindstrom S, Haggkvist B, Adami HO, Balter K, Stattin P, Ask B, Rane A, Ekstrom L, Gronberg H: **The UGT2B17 gene deletion is not associated with prostate cancer risk.** *Prostate* 2008, **68**:571–575.
 25. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH, Dossett N, Lang N, Kadlubar FF, Ambrosone CB, Zachariah B, Heysek R, Patterson S, Pow-Sang J: **Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.** *Cancer Epidemiol Biomarkers Prev* 2006, **15**:1473–1478.
 26. Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R, Pow-Sang J: **Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.** *Urology* 2007, **70**:374–379.
 27. Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, Stenzen B, Steiner E, Oldridge D, Kitabayashi N, Banerjee S, Chen JY, Schafer G, Horninger W, Lee C, Rubin MA, Klocker H, Demichelis F: **Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.** *Cancer Epidemiol Biomarkers Prev* 2010, **19**:229–239.
 28. Cunningham JM, Hebring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN: **Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.** *Cancer Epidemiol Biomarkers Prev* 2007, **16**:969–978.
 29. Gsur A, Preyer M, Haidinger G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M: **A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk.** *Cancer Epidemiol Biomarkers Prev* 2002, **11**:497–498.
 30. Hajdinjak T, Zagradisnik B: **Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: Frequency of DD homozygotes increases with Gleason score.** *Prostate* 2004, **59**:436–439.
 31. MacLeod SL, Nowell S, Plaxco J, Lang NP: **An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer.** *Ann Surg Oncol* 2000, **7**:777–782.
 32. Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, Helal M, Pow-Sang J: **Asp85Tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer.** *J Urol* 2004, **171**:2484–2488.
 33. Grant DJ, Hoyo C, Oliver SD, Gerber L, Shuler K, Calloway E, McPhail M, Livingston JN, Richardson RM, Schildkraut JM, Freedland SJ: **Association of UridineDiphosphate-Glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk.** *Genet Test Mol Biomarkers* 2012, **17**:1–7.
 34. Sun C, Southard C, Witonsky DB, Olopade OI, Di Renzo A: **Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15.** *Hum Mut* 2010, **31**:99–107.
 35. Antonelli JA, Jones LW, Banez LL, Thomas JA, Anderson K, Taylor LA, Gerber L, Anderson T, Hoyo C, Grant DJ, Freedland SJ: **Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.** *J Urol* 2009, **182**:2226–2231.
 36. Sun S, Southard C, Olopade OI, Di Rienzo A: **Differential allelic expression of c.1568C>A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3'UTR.** *Gene* 2011, **481**:24–28.
 37. Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treolar J, Giles GG, English DR, Hopper JL, Tilley WD, Mackenzie PI: **A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3alpha,17beta-diol glucuronide.** *Mol Pharmacol* 2010, **78**:714–722.
 38. Sun S, Southard C, Huo D, Hernandez RD, Witonsky DB, Olopade OI, DiRienzo A: **SNP discovery, expression and cis-regulatory variation in the UGT2B genes.** *Pharmacogenomics J* 2012, **12**:287–296.
 39. Okugi H, Nakazato H, Matsui H, Ohtake N, Nakata S, Suzuki K: **Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.** *Cancer Detect Prev* 2006, **30**:262–268.
 40. Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y: **Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8.** *J Hum Genet* 2002, **47**:505–510.
 41. Paquet S, Fazli L, Grosse L, Verreault M, Tetu B, Rennie PS, Belanger A, Barbier O: **Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.** *J Clin Endocrinol Metab* 2012, **97**:E428–E432.
 42. Chu DL, Moreira DM, Gerber L, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ: **Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting.** *Cancer* 2012, **118**:4999–5007.
 43. Zullig LL, Jackson GL, Dorn RA, Provenzale DT, McNeil R, Thomas CM, Kelley MJ: **Cancer incidence among patients of the U.S. Veterans Affairs Health Care System.** *Mil Med* 2012, **177**:693–701.

doi:10.1186/1471-2407-13-556

Cite this article as: Vidal et al.: Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study. *BMC Cancer* 2013 **13**:556.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

